Value Investor
Start free

Xilio Therapeutics

XLO on Nasdaq. Market value $53m.

Watch this stockFree. We tell you when something changes.

Should I look at this?

We have not checked this company yet

This is not advice.

Compare with another stock

Who owns it

None of the long-term investors we follow own it. 26 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

9 investors own more than 5%.

  • GILEAD SCIENCES, INC.
    Passive investor
    19.9%0.0 pts
    Since 31 December 2025
  • BCLS II Equity Opportunities, LP
    Passive investor
    at least 10.0%+1.5 pts
    (filed with 2 related holders)
    Since 31 March 2026
  • ORBIMED ADVISORS LLC
    Passive investor
    at least 10.0%
    (filed with 1 related holder)
    Since 31 March 2026
  • Coastlands Capital Partners LP
    Passive investor
    at least 10.0%
    (filed with 3 related holders)
    Since 4 December 2025
  • Sirenia Capital Management LP
    Passive investor
    at least 9.9%
    (filed with 1 related holder)
    Since 31 March 2026
  • StemPoint Capital LP
    Passive investor
    at least 9.5%+1.1 pts
    (filed with 2 related holders)
    Since 30 June 2026
  • AbbVie Inc.
    Passive investor
    9.0%
    Since 11 February 2025
  • Frazier Life Sciences Public Fund, L.P.
    Passive investor
    at least 6.7%−3.2 pts
    (filed with 9 related holders)
    Since 31 December 2025
  • Frazier Life Sciences Public Overage Fund, L.P.
    Passive investor
    at least 4.4%−3.7 pts
    (filed with 4 related holders)
    Since 30 June 2025
  • Sold down below 5%
    Since 31 March 2026
  • BCLS II Investco, LP
    Passive investor
    Sold down below 5%
    Since 31 December 2025
  • Sold down below 5%
    Since 31 March 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $43,950 of shares on the open market. 2 sold $5,668, $5,668 of it under preset trading plans.

  • Shannon James Samuel
    Director
    Bought
    Date
    26 March 2026
    Shares
    5,000
    Price
    $8.79
    Value
    $43,950
  • Brennan Kevin M.
    SVP, FINANCE AND ACCOUNTING
    Sold
    under a preset trading plan
    Date
    2 January 2026
    Shares
    1,826
    Price
    $0.64
    Value
    $1,169
  • Frankenfield Christopher James
    Chief Financial Officer
    Sold
    under a preset trading plan
    Date
    2 January 2026
    Shares
    7,030
    Price
    $0.64
    Value
    $4,499

From Form 4 filings: insiders must report trades in their own company's shares within two days.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.